Kane Biotech Inc. (TSXV: KNE) said on August 25, 2026 that research on its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium, held August 3-5, 2026 in Kissimmee, Florida. The Winnipeg company described MHSRS as the premier scientific meeting focused on military medicine and medical research supporting military personnel and operational readiness, and said the release followed completion of its post-conference review and related follow-up discussions.
The presentation, entitled “Broad-Spectrum, Cavity-Filling Antimicrobial Gel Spray to Address Prolonged Field Care Wound Challenges,” was authored by Kane Biotech’s Drs. Huizinga, Sailer and Visvalingam and delivered by Lt. Col. Steven L.A. Jeffery, MD, FRCS (Plast), a consultant plastic surgeon and professor of wound study at Birmingham City University. Kane described Jeffery as an expert adviser to the National Institute for Health and Care Excellence Medical Technologies Evaluation Programme, a co-founder of the charity Woundcare 4 Heroes and a burn surgeon in Ukraine. The subject was the potential use of revyve Antimicrobial Wound Gel Spray in prolonged field care, particularly in austere settings where access to advanced medical care may be delayed.
What the company disclosed, and what it did not
Kane said that as a result of its participation at MHSRS it was approached by several researchers interested in exploring applications of revyve in military, prolonged field care and complex wound management settings, and that it is working with them to develop a clinical research plan. No contract, procurement commitment, funding arrangement or revenue figure was announced alongside the presentation. The disclosed next step is planning work, not a trial that has started.
Jeffery’s assessment in the release was framed as a clinical opinion rather than trial data. He said the technology’s “ability for contactless rapid delivery and ability to conform to irregular wound cavities while maintaining contact with the wound bed makes it particularly interesting for patients with complex wounds and for environments where practical, effective wound management solutions are needed.” Robert Huizinga, the company’s interim chief executive officer, said Kane was pleased by the interest generated and that military medicine presents some of the most demanding wound care challenges.
The regulatory position behind the product is more concrete than the symposium news. The U.S. Food and Drug Administration’s 510(k) database records three clearances for Kane Biotech, Inc. under product code FRO: K223259 and K241809 for coactiv+ Antimicrobial Wound Gel, decided in 2023 and 2024, and K252759 for revyve Antimicrobial Skin and Wound Cleanser, decided in January 2026. Kane says the revyve gel, gel spray and cleanser are all 510(k) cleared and that the gel and gel spray are additionally approved by Health Canada. A 510(k) clearance establishes substantial equivalence to a legally marketed device; it is not a finding of clinical benefit in any particular setting, including the field care setting the presentation addressed.
The commercial base the news sits on
Two days after the symposium release, on August 27, 2026, Kane reported second quarter results that put the scale of the business in view. Total revenue for the three months ended June 30, 2026 was $8,143, against $27,997 a year earlier, with the prior-year figure consisting entirely of legacy animal health and DermaKB sales from businesses the company has since exited. Gross profit was $1,444, compared with a gross loss of $45,526 in the second quarter of 2025.
Operating expenses rose to $785,927 from $229,930, which Kane attributed primarily to stock option expense in the current period and one-time reversals of compensation accruals in the comparative period, partly offset by lower administration and research costs. The net loss widened to $833,636 from $348,541. Cash at June 30, 2026 was $854,729.
Alongside the numbers Kane set out programme milestones: clinical evaluations and case series underway or pending research approval at multiple sites in Canada and the United States, a North American revyve real-world data registry initiated, a scientific advisory board whose first meeting is planned for the fourth quarter of 2026, contract manufacturing scale-up for the cleanser, and biocompatibility testing for the DispersinB hydrogel due to start in the third quarter of 2026 ahead of a safety clinical trial targeted for 2027. Huizinga also said the company had completed additional financing and initiated a strategic review process.
On September 2, 2026 Kane announced a non-exclusive distribution agreement with Ontario Medical Supply Inc., an Ottawa-based distributor that Kane described as one of only two authorized distributors and price agreement holders for Ontario Health atHome. Kane cited Ontario Health atHome figures of more than 680,000 patients served annually and 11.1 million nursing visits in 2024-25, and published estimates that wound care accounts for roughly 40 to 50 per cent of home-care nursing visits.
Analysis: a credential, measured against a $8,143 quarter
The gap between the two August releases is the story. A presentation at a U.S. military medical meeting, delivered by a named consultant surgeon with NICE advisory standing, places the technology in front of that audience; it is not a commercial transaction. Two days later the same company reported quarterly revenue of $8,143 and cash of $854,729 against a net loss of $833,636. The symposium news changes the evidence file for revyve. It does not change the sales line, and the company did not claim it would.
The disclosure separates the two explicitly. Kane said researchers approached it and that a clinical research plan is being developed. It did not name the researchers, their institutions, a study design, a timetable or a funding source. The only step the release commits the company to is developing that plan. For a reader, the test is whether a named study with a registered protocol follows, and on what timetable.
The regulatory record supports the same reading. The 510(k) clearances on file cover wound gel and a skin and wound cleanser under a single product code, on decision dates running from 2023 to 2026. Clearance of that kind speaks to marketing authorisation, not to performance in prolonged field care, which is precisely the question the MHSRS presentation raised and did not answer. The clinical evaluations, case series and real-world registry described in the quarterly update are where an answer would come from.
The near-term markers are the ones Kane itself has dated. Biocompatibility testing for DispersinB was to begin in the third quarter of 2026, the scientific advisory board meets in the fourth, and the safety clinical trial is targeted for 2027. The Ontario Medical Supply agreement, announced on September 2, 2026, is the first distribution step tied to a specific formulary route rather than to general market development, and the quarterly revenue line is where it would show up. Against $854,729 of cash at June 30 and quarterly operating expenses of $785,927, the completed financing and the strategic review Huizinga mentioned are the other dated items in the same disclosure.
